Title Page

Gut microbiota impacts bone via *B.vulgatus*-valeric acid-related pathways

Xu Lin [2, 1, #], Hong-Mei Xiao [3, #, *], Hui-Min Liu [3], Wan-Qiang Lv [3], Jonathan
Greenbaum [1], Si-Jie Yuan [2], Rui Gong [2], Qiang Zhang [1], Yuan-Cheng Chen [2], Cheng
Peng [2], Xue-Juan Xu [2], Dao-Yan Pan [2], Zhi Chen [2], Zhang-Fang Li [2], Rou Zhou [2],
Xia-Fang Wang [2], Jun-Min Lu [2], Zeng-Xin Ao [2], Yu-Qian Song [2], Yin-Hua Zhang [2],
Kuan-Jui Su [1], Xiang-He Meng [1], Chang-Li Ge [4], Feng-Ye Lv [4], Xing-Ming Shi [5], Qi
Zhao [6], Bo-Yi Guo [7], Neng-Jun Yi [7], Hui Shen [1], Christopher J. Papasian [8], Jie Shen [2,
9, *], Hong-Wen Deng [1, 3, *]

1 Tulane Center for Bioinformatics and Genomics, School of Public Health and
Tropical Medicine, Tulane University, New Orleans, LA 70112, USA

2 Department of Endocrinology and Metabolism, The Third Affiliated Hospital of
Southern Medical University, Guangzhou 510630, China

3 Center of System Biology, Data Information and Reproductive Health, School of
Basic Medical Science, Central South University, Changsha 410008, China

4 LC-Bio Technologies (Hangzhou) CO., LTD., Hangzhou 310018, China

5 Departments of Neuroscience & Regenerative Medicine and Orthopaedic Surgery,
Medical College of Georgia, Augusta University, Augusta, GA, USA

6 Department of Preventive Medicine, College of Medicine, University of Tennessee
Health Science Center, Memphis, TN 38163, USA

7 Department of Biostatistics, University of Alabama at Birmingham, Alabama 35294,
USA

8 Department of Basic Medical Science, School of Medicine, University of
Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO 64108

9 Shunde Hospital of Southern Medical University (The First People's Hospital of
Shunde), No.1 of Jiazi Road, Lunjiao, Shunde District, Foshan City, Guangdong
Province, China

# These authors contributed equally to this work. Correspondence should be
addressed to Hong-Wen Deng (hdeng2@tulane.edu), Jie Shen (shenjiedr@163.com)
and Hong-Mei Xiao (hmxiao@csu.edu.cn).

Abstract

Although gut microbiota influences osteoporosis risk, the individual species involved, and underlying mechanisms, are unknown. We performed integrative analyses in a Chinese cohort with metagenomics/targeted metabolomics/whole-genome sequencing. *Bacteroides vulgatus* was found negatively associated with bone mineral density (BMD), this association was validated in US Caucasians. Serum valeric acid was positively associated with BMD, and *B.vulgatus* causally downregulated it. Ovariectomized mice fed *B.vulgatus* had decreased bone formation and increased bone resorption, lower BMD and poorer bone micro-structure. Valeric acid suppressed NF-κB p65 protein production (pro-inflammatory), and enhanced IL-10 mRNA expression (anti-inflammatory), leading to suppressed maturation of osteoclast-like cells, and enhanced maturation of osteoblasts *in vitro*. *B.vulgatus* and valeric acid represent promising targets for osteoporosis prevention/treatment.

1 Osteoporosis (OP), mainly characterized by low bone mineral density (BMD), predisposes to osteoporotic fracture, and is most prevalent in postmenopausal women (termed postmenopausal osteoporosis (PMOP)). 4.9 million post-menopausal women in US had osteoporotic fractures between 2000 and 2011, with greater hospital costs than myocardial infarction, stroke, and breast cancer [1,2]. The pathogenic mechanisms for PMOP and OP remain unclear, and current intervention and treatment options are not satisfactory [1,2].

9 Human studies have focused on the potential impact of inherent (e.g., (epi-)genome, transcriptome, proteome, metabolome) and external (e.g., environmental, medical/medication/nutrition, lifestyle) risk factors for OP [3]. Recently, however, experimental animal models have identified strong associations between gut microbiota (GM) and bone [4]. For example, Sjogren *et al.* found that absence of GM in mice leads to increased bone mass that normalizes following GM colonization [5]. In humans, four studies suggested the potential importance of GM for bone health [6-9], however, these studies had small sample sizes and did not identify specific bacterial species and associated functional mechanisms.

19 To identify specific significant gut bacterial species and their functional mechanisms on bone health, we performed a novel systematic integrative multi-omics analysis of the human genome, GM and targeted metabolome [serum short chain fatty acids (SCFAs)] in 517 peri- and post-menopausal Chinese women. We identified several

bacterial species SCFAs and functional pathways that significantly impacted BMD. We validated the major results in US Caucasians and investigated causal roles of individual bacterial species and SCFAs in regulating bone metabolism *in vitro* in cells and *in vivo* in mice. Our work is the first to identify individual BMD-associated GM species and particularly GM-derived functional metabolites in humans, and establish specific pathogenic mechanisms by which GM influences OP risk. Our results lay a foundation for potential prevention/intervention/treatment of OP through GM and metabolome alteration.

Chinese study cohort characteristics

peri-/post-menopausal Chinese women were randomly recruited from Guangzhou City, China; 84% were post-menopausal and 16% peri-menopausal, based on years since menopause (YSM) [10]. Mean YSM and follicle stimulating hormone (FSH) levels were 1.96 years and 76.24 mIU/mL, respectively (Table 1). Age (mean ± standard deviation [SD], 52.85 ± 2.92 years) and body mass index (BMI) (22.97 ± 2.87 kg/m^2) were relatively homogeneous. Mean BMD of the lumbar spine (L1-L4), left total hip (HTOT, including femoral neck, trochanter, and inter-trochanter), femoral neck (FN), and ultra-distal radius and ulna (UD-RU) were 1.05 g/cm^2, 0.93 g/cm^2, 0.86 g/cm^2, and 0.40 g/cm^2, respectively. Based on WHO criteria, 54.5% of the subjects had normal BMD (T-score ≥ -1), 38.5% osteopenia (-2.5 < T-score < -1), and 7% OP (T-score ≤ -2.5). Lifestyle factors (e.g., alcohol consumption, smoking, calcium supplementation, exercise) and socioeconomic status (e.g., education and

family annual income) are shown in Extended Data (ED) Table 1. Stool DNA and

blood samples were collected for metagenomic, genomic, and metabolomic analyses.

Correlation between GM and BMD

We performed shotgun metagenomics sequencing on stool DNA samples and obtained

~7.35 Gbp/sample sequencing data on average. We calculated unigene (non-redundant

genes) counts at different sample sizes. The number of unigenes increased with

sample size, approaching a plateau (exceeded 7×10^6) with our study sample (Figure

1a), indicating that our sample size was appropriate, large and reasonably powerful

for this investigation.

We identified 10,303 species by taxonomy annotation

(ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/nr.gz). 62 species were non-rare (relative

abundance > 0.10%) [11] accounting for 61.02% of the whole GM. The rest were rare

species (Figure 1b). The 3 most common species were *Faecalibacterium prausnitzii*

(8.77%), *Bacteroides vulgatus* (7.46%), and *Bacteroides fragilis* (4.16%). 26 and 27

of the non-rare species had high positive (Spearman correlation coefficients [γ's] >

0.80, *p*-values < 0.001) and negative (γ's < -0.30, *p*-values < 0.001) correlations,

respectively, with one another (Figure 1c). This suggests that interactions between

GM species promote co-existence (when γ is > 0.80) or suppression (when γ is <

-0.30) of each other.

We used "vegan" package and Microbiome Regression-based Kernel Association Test (MiRKAT) [12] to calculate α-diversity (Shannon index) and β-diversity (optimal kernel, based on weighted and unweighted UniFrac distance matrices and Bray-Curtis distance), and evaluated their associations with BMD. GM biodiversity was negatively associated with forearm BMD (ED Table 2), including ultra-distal radius BMD (UD-R BMD, partial γ = -0.081, p-value = 0.072, p-value of MiRKAT = 0.005), ultra-distal ulna BMD (UD-U BMD, partial γ = -0.098, p-value = 0.029, p-value of MiRKAT = 0.014), and UD-RU BMD (partial γ = -0.097, p-value = 0.031, p-value of MiRKAT = 0.010). The p-value significance remained when adjusted with false discovery rate for multiple testing (q-values ~0.10 or less). Although no significant association was found between GM biodiversity and BMD at L1-L4 or HTOT, we hypothesized that individual bacterial species contributed to these phenotypes.

We performed constrained linear regression analysis [13], and found several individual species significantly associated with BMD (ED Table 3). Specifically, *Bacteroides vulgatus* (regression coefficient [β] = -0.027, p-value = 0.032), *Bacteroides thetaiotaomicron* (β = 0.027, p-value = 0.021), *Butyrate-producing bacterium_SS3/4* (β = -0.024, p-value = 0.040), *Clostridium bolteae* (β = 0.045, p-value = 0.036), and *Bacteroides sp_9_1_42faa* (β = 0.033, p-value = 0.031) were associated with L1-L4 BMD. Additionally, *Butyrate-producing bacterium_SS3/4* was associated with HTOT BMD (β = -0.022, p-value = 0.009) and FN BMD (β = -0.021, p-value = 0.014); *Bacteroides ovatus* was associated with UD-RU BMD (β = 0.011, p-value = 0.046);

and *Bacteroides intestinalis* was associated with HTOT BMD (β = -0.021, *p*-value = 0.043).

After function annotation and obtaining KEGG modules, we performed partial Spearman correlation analysis to identify relationships between GM functional capacity and BMD variation. Three functional modules were significantly negatively associated with L1-L4 BMD and four modules were negatively associated with UD-RU BMD (γ's < -0.10, *p*-values < 0.010) (Table 2). For example, for L1-L4 BMD, significantly associated modules included "M00002: glycolysis, core module involving three-carbon compounds", "M00048: inosine monophosphate biosynthesis, phosphoribosylpyrophosphate + glutamine $\rightarrow$ inosine monophosphate", and "M00855: glycogen degradation, glycogen $\rightarrow$ glucose-6P". All these modules involve pathways whereby GM produces metabolites from ingested foods, suggesting that these metabolites influence BMD.

SCFAs significantly associated with BMD

GM may affect host health through SCFAs [14]. Therefore, we analyzed serum SCFA levels by targeted metabolomics. By multiple linear regression analysis, valeric acid was positively associated with L1-L4 BMD (β = 0.040, *p*-value = 0.029). The results (non-significant) of other kinds of SCFAs (including caproic acid, isovaleric acid, butyric acid, acetic acid, and isobutyric acid) were shown in ED Table 4. Furthermore, five bacterial species were significantly associated with valeric acid (ED Table 5). *Alistipes putredinis*, *Bacteroides caccae*, and *Bacteroides cellulosilyticus* were

positively associated with valeric acid (β's > 0.05, p-values < 0.05, ED Table 5).

B.vulgatus and *B.intestinalis*, which were negatively associated with L1-L4 and

HTOT BMDs (ED Table 3), were also negatively associated with valeric acid (β's <

-0.10, p-values < 0.01, ED Table 5). Since only *B.vulgatus* was significantly

associated with both L1-L4 BMD and valeric acid, we subsequently focused on this

species.

Since valeric acid is produced by probiotic bacteria [15], we calculated the Spearman

correlation between *B.vulgatus* and common probiotic bacteria [16, 17]. The relative

abundance of *B.vulgatus* was negatively associated (γ = -0.24, p-value = 8.3×10^{-8})

with the sum of relative abundance of common probiotic bacteria (each still rare (<

0.10%) so pooled for analyses). We used Mendelian randomization (MR) approach [18]

to assess the potential causality of *B.vulgatus* (as exposure) on valeric acid (as

outcome), using their associated SNPs derived from whole genome sequencing for

human subjects as instrumental variables. Most MR methods, including the weighted

median method, maximum likelihood estimation, and inverse-variance weighted

indicated that *B.vulgatus* may causally down-regulate valeric acid (β's < -0.07,

p-values < 0.05) (ED Table 6). MR-Egger (intercept) result (p-value = 0.517) showed

no horizontal pleiotropy for *B.vulgatus* to influence valeric acid levels.

B.vulgatus/BMD associations in US Caucasians

To assess the robustness of our major findings, we tested associations between

B.vulgatus and human BMD in an independent cohort of 59 post-menopausal

Caucasian females, aged ≥ 60 years, in New Orleans, Louisiana. Mean (SD) age and

BMI were 66.98 (5.65) years and 27.84 (8.50) kg/m^2, respectively. Mean BMD for

L1-L4, HTOT, FN, UD-R, and UD-U were 0.92 g/cm^2, 0.80 g/cm^2, 0.67 g/cm^2, 0.37

g/cm^2, and 0.28 g/cm^2, respectively. Lifestyle information is shown in ED Table 7. We

detected an association between *B.vulgatus* and HTOT BMD (β = -0.018, *p*-value =

0.029), supporting *B.vulgatus*'s association with BMD in ethnically distinct

populations.

***In vivo* and *in vitro* validation**

To evaluate potential causal effects of *B.vulgatus* on bone metabolism (focusing on

lumbar vertebrae), we ovariaectomized (OVX) 8-week-old female C57BL/6 mice (n =

18) to model post-menopause, and performed oral gavage experiments. After

gavaging with *B.vulgatus*/normal saline (NS) for eight weeks after OVX, we found

lower BMD (*p*-value < 0.05, Figure 2a), increased disconnection and separation of the

trabecular bone network, and reduction of trabecular number (Figure 2d and Figure 2e)

in the *B.vulgatus* treated group. The *B.vulgatus* treated group also showed lower

(two-sample t-test, *p*-value < 0.05) bone formation levels (measured by serum

osteocalcin, Figure 2b) and higher (two-sample t-test, *p*-value < 0.05) bone resorption

levels (measured by type I collagen serum C-telopeptide, Figure 2c). This

demonstrates that *B.vulgatus* suppressed bone formation and promoted bone

resorption leading to reduced lumbar vertebral BMD and deteriorated bone

architecture.

Since our results suggested that *B.vulgatus* affects BMD by down-regulating valeric

acid production, we investigated the effects of valeric acid on osteoclast and

osteoblast differentiation *in vitro*. Murine macrophages (RAW264.7) and

pre-osteoblasts (MC3T3-E1) were differentiated with/without valeric acid. After

inducing osteoclast differentiation of RAW264.7 cells with RANKL (50 ng/mL), 5

days treatment with valeric acid (1 mM) significantly decreased the proportion of

mature osteoclast-like cells (TRAP positive and with $\geq$ 3 nuclei) vs. controls (Figure

3a), indicating that valeric acid significantly inhibited osteoclast differentiation.

Treatment with valeric acid (1 mM) for 14 days also significantly increased

differentiation of MC3T3-E1 into osteoblasts, and mineralization of the extracellular

matrix (Figure 3b). Therefore, valeric acid inhibited differentiation of osteoclast-like

cells, and promoted differentiation of, and mineralization by, osteoblasts.

Because inflammatory pathways play important roles in bone metabolism [19] and GM

may influence bone metabolism through its effects on inflammation [4], we measured

expression levels of several critical inflammatory genes (e.g., NF-κB p65 and IL-10)

in cultured osteoclast-like cells and osteoblasts. After treating osteoclast-like cells and

osteoblasts with valeric acid for 5 and 14 days, respectively, IL-10 (anti-inflammatory

cytokine) mRNA levels were significantly increased, while NF-κB p65

(pro-inflammatory) protein levels were decreased, compared to controls (Figures 3c to

3f). NF-κB p65 is a subunit of NF-κB, plays a critical role in the pathogenesis of multiple chronic inflammatory diseases by upregulating transactivation of inflammatory cytokines target genes [20]; while IL-10 is an anti-inflammatory cytokine [21]. Thus, valeric acid inhibited inflammatory responses of osteoclast-like cells and osteoblasts, which may explain its positive association with BMD, since inflammation may lead to bone loss [19], and the NF-κB can inhibit osteoblast functions [22].

Discussion

We found that: **1)** GM biodiversity was negatively associated with forearm BMD; **2)** several individual bacterial species were significantly associated with BMD; **3)** *B.vulgatus* was negatively associated with BMD in ethnically distinct populations; **4)** several bacterial metabolic pathways were negatively associated with BMD; **5)** serum valeric acid levels were positively associated with L1-L4 BMD; **6)** *B.vulgatus* was negatively associated with serum valeric acid levels; and **7)** *B.vulgatus* may causally suppress valeric acid levels, presumably by inhibiting growth of valeric acid producing bacteria within the gut.

Subsequent *in vivo* and *in vitro* studies found that **1)** bone formation was decreased, and bone resorption increased, in OVX female mice fed *B.vulgatus*; **2)** valeric acid suppressed maturation of osteoclast-like cells, and promoted maturation of osteoblasts and extracellular matrix mineralization by osteoblasts *in vitro*; **3)** valeric acid treatment of osteoclast-like cells and osteoblasts *in vitro* suppressed NF-κB p65

protein production (pro-inflammatory), and enhanced IL-10 mRNA expression

(anti-inflammatory). Thus, *B.vulgatus* appears to decrease BMD by reducing valeric

acid production within the gut, resulting in enhanced inflammation and osteoclast

activity, and reduced osteoblast activity.

The negative association between GM biodiversity and BMD in our discovery sample

is consistent with previous reports. Wang *et al.* found elevated diversity in OP and

osteopenia groups compared with controls [8], and Das *et al.* found a trend of higher

Shannon index (α-diversity) in OP and osteopenia groups compared with controls (Fig

3D in [6]) [6]. Germ-free mice (no GM biodiversity exists) had higher bone mass than

mice with normal GM [5], and that antibiotic treatment of mice early in life reduced

GM biodiversity and increased bone size [23]. Although GM biodiversity is generally

believed to be beneficial [24], the above results suggest that the effects of GM

biodiversity on health vary with the trait studied, environmental factors (e.g. diet and

exercise) and individual species composition within GM.

In our study, *B.vulgatus* was negatively associated with L1-L4 BMD in the Chinese

cohort (β = -0.027, *p*-value = 0.032), which has a consistent association with HTOT

BMD in the US cohort (β = -0.018, *p*-value = 0.029). In fact, *B.vulgatus* tended to be

consistently negatively (though non-significantly in many cases) associated with

BMDs at all the measured various other skeletal sites in both of the two human

cohorts (ED Table 8). To evaluate the overall effects of *B.vulgatus* on BMD, we

further performed one-sided sign test [25] based on the coefficients of the regression of

individual skeletal sites with *B.vulgatus* (ED Table 8). The null hypothesis (H0) is that

regression coefficients are equal to zero. The alternative hypothesis (H1) is that

regression coefficients are less than zero. The results indicated clearly that overall,

there were significant negative associations between BMDs and *B.vulgatus* in both of

the Chinese and the US cohorts (*p*-value_Chinese = 4.8 $\times$ 10^{-7}, *p*-value_US = 9.8

$\times$ 10^{-4}). In genomics studies, it is not uncommon to observe that a particular gene

was significantly associated with different skeletal sites of BMDs in different

populations. An example is given by the most prominent *WNT16* gene, which was

found to be associated with BMD at different skeletal sites in different cohorts [26]. The

association and partial validation between *B.vulgatus* and BMD in the human cohorts

was only mainly for discovery relative to the following-up functional validation

studies. Following discoveries in humans, we subsequently validated the results by

various *in vivo* and *in vitro* experiments. All of the results together furnish strong

evidence for the significance of *B.vulgatus* on BMD and bone metabolism.

B.vulgatus is one of the most abundant bacteria in human gut [27], and can trigger

proinflammatory NF-κB signaling pathways [27] associated with bone remodeling [28]. To

determine how GM influences BMD, we examined relationships between GM

functional capacity and BMD variation. Most GM functional modules negatively

associated with BMD (Table 2) involved GM metabolism. M00002, M00003 and

M00855 involved glycolytic pathways or gluconeogenesis, both of which affect

glucose metabolism, essential for cellular energy [29]. Modules M00048 and M00050

both involve nucleic acid synthesis required for bacterial growth [30, 31]. These

collective findings demonstrate that human bone health is affected by GM, and that

specific bacterial biosynthetic/metabolic pathways, contribute to these effects.

Since several GM functional modules were associated with BMD, and microbial

metabolites contribute to host-microbiome interactions [32], we explored relationships

between BMD and serum SCFAs. SCFAs are produced exclusively by GM [15],

absorbed in the colon [15], and function as critical signalling molecules between the host

and GM [15]. Regarding the potential impact of SCFAs on bone health, butyrate has

been reported to inhibit osteoclast differentiation and bone resorption in mice [14, 33]. In

the current study, we found that valeric acid (an SCFA) was positively associated with

BMD, inhibited differentiation of osteoclast-like cells, and promoted differentiation

and mineralization of osteoblasts. Valeric acid also suppressed NF-κB p65 protein

production (pro-inflammatory), and enhanced expression of IL-10 mRNA

(anti-inflammatory) by osteoclast-like cells and osteoblasts. This is consistent with

previous reports that SCFAs reduced macrophage induced inflammation by

suppressing NF-κB, and increasing IL-10, expression [34]. IL-10 inhibits NF-κB

production [35], and NF-κB promotes inflammation, which contributes to bone loss [19],

and inhibits osteoblasts, which reduces new bone formation [22]. These collective

results are consistent with the conclusion that the protective effect of valeric acid on

BMD is partially attributable to decreased osteoclast activity and increased osteoblast

activity through increased IL-10 expression, and direct (via valeric acid) or indirect

(via IL-10) inhibition of NF-κB expression [28]. Valeric acid inhibits histone deacetylase

(HDAC), an enzyme that is important for epigenomic regulation of gene expression [36].

HDAC is implicated in the pathogenesis of a number of diseases (e.g., cancer, colitis,

cardiovascular disease and neurodegeneration), and HDAC inhibitors are considered

as potential therapeutic agents [36]. In irradiated mice, valeric acid can protect

hematogenic organs, improve gastrointestinal tract function and enhance intestinal

epithelial integrity to elevate survival rate [37]. Our study here for the first time suggest

that valeric acid could be used to treat/prevent OP.

Since both *B.vulgatus* and valeric acid were associated with BMD, we sought to

determine whether *B.vulgatus* regulated bone metabolism by decreasing valeric acid

levels. Regression and MR analyses demonstrated that *B.vulgatus* was negatively

associated with valeric acid, and may causally down-regulate valeric acid levels. We

also observed negative correlations between *B.vulgatus* and common gut probiotic

bacteria [16, 17]. Bacterial fermentation product levels (e.g., valeric acid) depend on the

relative abundances of different GM populations, and on competitive and cooperative

interactions between different GM species [38]. GM in humans is dominated by negative

interactions, and the *Bacteroidales*, which includes *B.vulgatus*, commonly express

molecular mechanisms for delivering toxic payloads to other bacteria [39]. Consequently,

we speculate that *B.vulgatus* competitively inhibits growth of valeric acid producing

probiotic bacteria, thereby reducing valeric acid levels.

In this study, we pioneered an innovative and comprehensive multi-omics approach for discovery in a Chinese cohort, followed by *in vitro* and *in vivo* functional validation experiments plus replication in an independent cohort of US Caucasians. We, for the first time, successfully identified and validated individual gut bacterial species, and their derived metabolites, that were significantly associated with human BMD. These findings provide a potential novel target and pathway for OP prevention and treatment during the critical menopausal period in aging women.

There are several strengths of our study. First, to our knowledge, this is currently the largest metagenomics study directly testing associations between GM and human BMD. Second, we used stringent inclusion and exclusion criteria to ensure that subjects were relatively homogeneous for age, ovarian function and living environment, thereby minimizing potential confounding factors. Third, functional mechanisms contributing to associations between GM and BMD were identified by using an innovative multi-omics approach to generate a comprehensive understanding of crosstalk, interactions, and causal inference of the interactions, between GM and human BMD. Finally, we used both statistical and experimental evidences to demonstrate the effects of specific bacterial species and GM-derived metabolites on BMD variation and regulation, and the causal effects of specific gut bacterial species on GM-derived metabolites in human serum.

In conclusion, our study provides compelling evidence for associations between GM, SCFAs and human BMD. Importantly, we demonstrated that *B.vulgatus* appears to play a critical role in regulating bone metabolism, through its effects on valeric acid production. Valeric acid, in turn, promotes differentiation and mineralization of osteoblasts, and suppresses osteoclast differentiation and inflammatory responses by osteoblasts and osteoclast-like cells. Our findings provide novel insights into the pathophysiological mechanisms of OP from a novel perspective of human microbiota and their functional products, SCFAs, in human serum and suggested potential new biomarkers (e.g., valeric acid) and treatment targets (e.g., elimination of *B.vulgatus* from the gut; dietary supplementation with valeric acid) for OP prevention/intervention/treatment.

Online Methods

Subjects recruitment and sample preparation

This study was approved by the Third Affiliated Hospital of Southern Medical University (Guangzhou City, China). It was performed under the principle of the Helsinki Declaration II. 517 independent unrelated peri-/post-menopausal Chinese women were recruited. The inclusion criteria included **1)** aged 40 years or older, **2)** being in menopause stage, and **3)** had lived in Guangzhou City for at least three months. Menopause is marked by the cessation of menstruation, where peri-menopause is a transition phase beginning at a woman's last menstrual cycle and continuing through the following 12 months without a menstrual cycle; once there are

no menstrual cycles for 1 year, we term it post-menopause [10]. Briefly, exclusion

criteria included the use of antibiotics, oestrogens, or anticonvulsant medications

which may affect gut microbiota (GM) composition and/or bone metabolism in the

past three months, as well as other diseases that could lead to secondary osteoporosis

(OP). A detailed list of exclusion criteria is shown in Extended Data (ED) Table 9. We

obtained signed informed consent from each subject before enrolling them into this

study. Each subject filled out a questionnaire that collected information on age,

medical history, family history, physical activity, alcohol consumption, diet habits,

smoking history, nutrition supplements, etc.

We used a GE Lunar dual energy X-ray absorptiometry (DXA, GE Healthcare,

Madison, WI, USA, version 13.31.016) with a standard scan model to measure the

bone mineral density (BMD) of each subject at various skeletal sites, including the

lumbar spine (L1-L4), left total hip (HTOT), femoral neck (FN), ultra-distal radius

and ulna (UD-RU). We performed DXA scanner calibration with a daily special

phantom scan for quality assurance. The accuracy of various skeletal sites BMD

measurement was assessed by the coefficient of variation (CV%) of spine BMD,

which was 0.89%.

Blood and stool samples were collected from each subject. Blood samples were

collected after an overnight fast for > 8 hours, and used for serum analysis and DNA

extraction with the SolPure DNA Kit (Magen, Guangzhou, China). Each faecal

sample was frozen at -80 °C within 30 min of sample procurement, and used for GM

DNA extraction with the E.Z.N.A.® Stool DNA Kit (Omega, Norcross, GA, USA).

1   We stored the serum, blood and GM DNA samples at -80 °C until further analyses.

Metagenomic shotgun sequencing and annotation

DNA library construction

Shotgun metagenomic sequencing was performed by LC-Bio Technologies (Hangzhou) CO., LTD. (Hangzhou, China, www.lc-bio.com; this company owns an LC Sciences R&D department in Houston, TX, USA, www.lcsciences.com). We constructed a faecal DNA library, and used Hiseq 4000 (Illumina, San Diego, CA, USA) and PE150 strategy to conduct metagenomic shotgun sequencing. The relative abundance of unigenes for a sample was estimated by transcripts per kilobase million (TPM, Formula 1, where k was the kth unigene, r was number of unigene reads, and L was unigene length) based on the number of aligned reads and the unigene length by Bowtie2 v2.2.0.

$$G_k = \frac{r_k}{L_k} \times \frac{1}{\sum_{i=1}^{n} \frac{r_i}{L_i}} \times 10^6 \quad (1)$$

Taxonomic and functional annotation of unigenes

The unigenes were aligned against the NCBI NR database (ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/nr.gz) by DIAMOND software [40] with lowest common ancestor algorithm [41] for taxonomic annotation, and against protein reference based on the KEGG pathway dataset (https://www.genome.jp/kegg/pathway.html) for functional annotation. The relative abundance of each annotated functional module was the sum of relative abundance of

the unigenes within this module. We chose the modules whose relative abundance >

0.10% to estimate the association between the KEGG modules and BMD variation by

performing partial Spearman correlation analysis, and adjusted for a number of

covariates, including age, body mass index (BMI), years since menopause (YSM),

follicle stimulating hormone (FSH), exercise, and family annual income. Results with

p-values < 0.01 were considered statistically significant.

Detailed information about faecal DNA library construction, raw data preprocessing

and cleaning, taxonomic and functional annotation of unigenes, was shown in

supplementary information.

Unigene accumulation curve construction and species biodiversity calculation

We first counted the number of unigenes at different sample sizes. The R package

"ggplot2" was used to generate a unigene accumulation curve. We plotted the number

of unigenes (Y-axis) against the number of samples (X-axis).

The α-diversity of GM was estimated based on the species profile of each sample

according to the Shannon index by using R package "vegan". Then, partial Spearman

correlation analysis was performed to estimate the association between the Shannon

index and BMD variation. The association between bacterial species profiles and

BMD variation was calculated by the program Microbiome Regression-based Kernel

Association Test (MiRKAT) [12], by which we first calculated different kinds of kernels

(including weighted and unweighted UniFrac distance matrices and Bray-Curtis

distance), and then obtained the optimal kernel to estimate the association between

1 GM species profiles and BMD variations. In these analyses, we adjusted the same set

2 of covariates as the KEGG modules analysis mentioned above. Results with *p*-values

3 less than 0.05 were considered statistically significant.

5 Measurement of short chain fatty acids (SCFAs)

2 μl of the supernatants extracted from serum samples were analyzed with gas

chromatography-tandem mass spectrometry (GC-MS/MS, 7890B-7000D, Agilent

Technologies Inc, Santa Clara, CA, USA) by Wuhan Metware Biotechnology Co., Ltd

(Wuhan City, China, www.metware.cn) based on a fused silica capillary column

(DB-FFAP, 30 m x 0.25 mm x 0.25 μm, Agilent Technologies Inc, Santa Clara, CA,

USA). Then we constructed standard curves to calculate concentration of SCFAs.

Detailed conditions of GC-MS/MS, quality control (QC), preparation of SCFAs

calibration standards, and SCFAs concentration calculation by standard curves, were

shown in supplementary information.

16 Association analysis among GM, SCFA, and BMD

We treated BMD as a continuous variable and then explored the association among

GM, SCFA, and BMD by using different association analysis methods. In this study,

we focused on non-rare species (relative abundance > 0.10%) because rare species

typically contribute significantly less to functional diversity than non-rare species due

to their low abundances [42]; meanwhile, the rare species are generally difficult to

cultivate [42], which might make our subsequent experimental validation *in vivo*

difficult.

For the association analysis, first, we used the "igraph" package and the "psych"

package of R software to identify correlations between bacterial species. Spearman

correlation analysis was performed on the relative abundance of each bacterial species.

Meanwhile, we used the same method to identify correlations between specific

bacterial species and probiotic bacteria reported in two previous reviews which

summarized the most notable probiotics [16, 17]. The reported probiotic bacteria were

pooled for such analyses due to the small relative abundances of each of the

individual species (less than 0.10%). Furthermore, the R package "pheatmap"

package was used to create a heatmap for visualization of the bacterial species

correlation.

Second, for those highly correlated bacterial species (with correlation coefficients [γ's]

≥ 0.80) that might cause a multiple co-linearity problem, we retained the bacterial

species with a higher relative abundance and removed others as bacteria with

relatively higher relative abundance may render higher power in association testing.

Constrained linear regression analysis [13] was then performed by using Stata 14

software with the "cnsreg" function, in which BMD variation was considered as the

dependent variable, and the relative abundance of bacterial species was set as the

independent variable. A number of covariates were adjusted in the regression analysis,

including age, BMI, YSM, FSH, exercise, and family annual income. The threshold of

exercise was 2.5 hours per week based on a published guideline [43]. The family annual

income was separated according to the local economic report. As microbiome data are

often obtained at different taxonomic ranks (including species, genus, family, order,

class and phylum), we performed subcomposition analysis using previously published

protocols [13], and converted the bacterial species relative abundance data into

subcompositions within each phylum by centered log ratio transformation, to find out

which bacterial species within a given phylum is associated with BMD variation. The

formula of constrained linear regression analysis is shown below (Formula 2), where

p was the phylum level, n was the number of phyla, s was species level, and m was

the number of bacterial species. Bacterial species with a p-value of the regression

coefficient (β) less than 0.05 were defined as BMD-associated bacterial species.

$$Y(BMD) = \sum_{p=1}^{n} \sum_{s=1}^{m} \beta_{ps} \mathrm{CLR}(X_{ps}) + \beta * \text{covariates}$$

$$\sum_{s=1}^{m} \beta_{ps} = 0 \tag{2}$$

Third, we used multiple linear regression analysis to identify BMD-associated SCFAs

(Formula 3), where we performed log transformation for the SCFA concentration

because of their non-normalization distribution and adjusted the same set of

covariates mentioned above.

$$Y(BMD) = \sum \beta_i * log(X_i) + \beta_j * \text{covariates}_j \tag{3}$$

Finally, we performed constrained linear regression analysis (Formula 4) to identify

SCFA-associated bacterial species, while adjusting for age, BMI, YSM, and FSH as

covariates.

$$Y(\log(\text{individual SCFA})) = \sum_{p=1}^{n} \sum_{s=1}^{m} \beta_{ps} \mathrm{CLR}(X_{ps}) + \beta * \text{covariates}$$

$$\sum_{s=1}^{m} \beta_{ps} = 0 \tag{4}$$

Replication in the Caucasian cohort

A total of 59 Caucasian females, aged 60 years or older, were recruited from the ongoing Louisiana Osteoporosis Study (from 2011 to current), which aims to build a large sample pool in greater New Orleans and surrounding areas in Southern Louisiana, USA for investigating genetic and environmental factors for musculoskeletal disorders [44]. This study was approved by the institutional review board of Tulane University (New Orleans, LA, USA), and a written consent form was signed by each participant before data and bio-sample collection. Individuals who had pathological conditions that may influence BMD (e.g., a bilateral oophorectomy, chronic renal failure, liver failure, lung disease, gastrointestinal diseases, and inherited bone diseases), or may influence GM (e.g., taking antibiotics, having gastroenteritis, major surgery involving hospitalization, and inter-continental travel in the past three months) were excluded. For each participant, BMD was measured by using a Hologic Discovery-A DXA machine (Hologic Inc., Bedford, MA, USA) and information on age, medical history, physical activity, alcohol consumption, diet habits, smoking history, and nutrition supplements was assessed by a questionnaire. The accuracy of BMD measurement as assessed by the CV% of L1-L4 BMD was 0.54%. The shotgun metagenomics sequencing on the collected faecal samples were performed by Alkek Center for Metagenomics and Microbiome Research (CMMR), Baylor College of Medicine. We conducted partial Spearman correlation analysis for the identification of correlation between GM biodiversity and BMD variation, and we also used

constrained linear regression analysis (Formula 2), as described above, to identify

BMD-associated individual bacterial species. The covariates included age, BMI,

exercise, and bone fracture.

In vivo* mouse experiment with *B.vulgatus

Ovariectomy (OVX) and B.vulgatus gavage

All the procedures involving mice were approved by the Southern Medical University

Animal Management Committee (Guangzhou City, China). Seven-week-old female

C57BL/6 mice (specific-pathogen free grade) were purchased from the Laboratory

Animal Center of the Southern Medical University (Guangzhou, China). The mice

were fed freely with food and water for one week to acclimate to the new

environment before experiments. Then bilateral OVX surgery was performed with

general anaesthesia by the dorsal approach because eight-week-old C57BL/6J mice

are suitable animal model for postmenopausal osteoporosis [45]. After one week for

recovery, the mice were separated randomly into two groups (9 samples/group):

Group I mice were gavaged with 100 μl of *B.vulgatus* (ATCC8482, 5×10^8

colony-forming units/mouse, ATCC, Manassas, VA, USA; lot number: 70009621),

while Group II mice were gavaged with 100 μl of normal saline (NS). *B.vulgatus* was

cultivated according to the product description and harvested in log phase for gavage.

All mice were gavaged every other day and continued to feed freely with common

food and water under the same environmental conditions. After gavaging for eight

weeks, the mice were sacrificed and used for blood and bone measurements.

BMD measurement and bone morphology evaluation by micro-computed tomography

(μCT)

We used LaTheta LCT 200 μCT (Aloka, Japan) to measure the BMD of the 5th lumbar

vertebral body. The instrument accuracy was 1 ± 0.005 mg/cm^3. We performed

phantom scan at first for QC. Then we scanned the lumbar spine to obtain lumbar

vertebral body BMD. Meanwhile, for visualization and comparison of bone

microstructure changes, we randomly selected a bone sample (the 5th lumbar vertebrae)

from each of the two mice groups (Group I with *B.vulgatus* gavage and Group II with

NS gavage), and used μCT100 (Scanco Medical AG, Bassersdorf, Switzerland) with a

resolution of 7.4 μm for three-dimensional reconstruction.

Analysis of serum biomarkers

We used ELISA kits to measure osteocalcin (Cloud-Clone Corp, Katy, TX, USA) and

C-telopeptide of type I collagen (Cusabio, Houston, TX, USA), which are markers of

bone formation and bone resorption, respectively.

Histomorphometry

We used hematoxylin-eosin (ZSGB-BIO, Beijing, China) staining to assess

histomorphology of trabecular bone in the 5th lumbar vertebrae.

Statistical analysis

We used two-sample t-test to identify whether BMD and serum biomarkers were

significantly different between the two groups.

Details about scanning parameters of μCT and histomorphometry process were shown

in supplementary information.

Mendelian randomization (MR) analysis for BMD-associated GM and SCFA

Whole genome sequencing (WGS)

WGS was performed by BGI Genomics Co. Ltd (Shenzhen, China;

https://www.genomics.cn/) with BGISEQ-500 platform.

Details including quality control were shown in supplementary information.

Genome-wide association study (GWAS)

We used PLINK 1.9 software with the default criteria as follows to identify *B.vulgatus*

and valeric acid-associated SNPs: the SNPs with missing call rate < 0.1, minor allele

frequencies > 0.01, and Hardy-Weinberg equilibrium *p*-value > 1.0×10^{-5} were

included for subsequent analyses.

MR analysis

Based on *B.vulgatus* and valeric acid GWAS results, we investigated the causality of

B.vulgatus exposure on valeric acid outcome with one-sample MR analysis, which is

a commonly used method. One-sample MR analysis uses genetic variants, exposure,

and outcome from the same individua, which provides greater control of the analysis

(such as determining exposure category - a continuum or in categories, examining

associations between genetic instruments and confounders) than two-sample MR

analysis [46]. For the implementation of MR, we first selected independent genetic

variants ($r^2 \leq 0.001$) associated with the *B.vulgatus* (*p*-values $< 1 \times 10^{-5}$) as the

instrumental variables (IVs) as done earlier [47]. We then obtained the corresponding

effect estimates of these SNPs from the valeric acid GWAS analysis. When the target

SNPs were not available in the valeric acid GWAS result, we used proxy SNPs that

were in high linkage disequilibrium (LD, $r^2 > 0.80$) with the SNPs of interest. The

proxy SNPs were identified based on 1000 genomes project data [48]. To ensure the

SNPs used as IVs for *B.vulgatus* are not in LD with one aother, a vital assumption of

MR, we calculated pairwise-LD between all of our selected SNPs in the 1000

Genomes European reference sample using PLINK 1.9. For all the pairs of SNPs

determined to violate the independence assumption with $r^2 > 0.01$, we retained only

the SNPs with the smaller *B.vulgatus* association *p*-values. Overall, we obtained 15

LD-independent SNPs that achieved genome-wide significance for *B.vulgatus* and

valeric acid. Therefore, these 15 SNPs remained for performing the MR analysis

(Extended Data Table 10). Weighted median method, maximum likelihood estimation

(MaxLik) and inverse-variance weighted (IVW) [49] were performed to identify causal

relationships between *B.vulgatus* and valeric acid by weighting the effect estimate of

each SNP on valeric acid with its effect on *B.vulgatus*. Because SCFA was only

produced from GM [14], we only chose single direction MR (*B.vulgatus* as exposure

and valeric acid as outcome) rather than bidirectional MR analysis. Because the

presence of horizontal pleiotropy could bias the MR estimates, we used the intercept

that deviates from the MR-Egger method to examine the presence of horizontal

pleiotropy as described in the previous study [47].

Effects of valeric acid on osteoclastogenesis and osteoblastogenesis

In vitro differentiation of osteoclast-like cells

We used the murine monocyte/macrophage cell line RAW264.7 (Chinese Academy of

Sciences Cell Bank, Shanghai, China) as osteoclast precursors, which can

differentiate into osteoclast-like cells in the presence of receptor activator of nuclear

factor-κB ligand (RANKL, 50 ng/mL, PEPROTECH, Rocky Hill, NJ, USA). The

cells were grown in Dulbecco's Modified Eagle Medium (DMEM,

GIBCO/Invitrogen, Carlsbad, CA, USA), containing 10% fetal bovine serum (FBS,

GIBCO/Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin and 100 mg/ml

streptomycin sulfate (GIBCO/Invitrogen, Carlsbad, CA, USA), at 37˚C in a

humidified atmosphere of 95% air and 5% CO_2, and treated with various

concentrations (0, 0.001, 0.01, 0.1, 1 mM) of valeric acid (TCI, Tokyo, Japan). We

changed the medium every other day, and fixed the cells at the end of the 5th day.

Then we performed tartrate-resistant acid phosphatase (TRAP) staining (Solarbio,

Beijing, China) to observe TRAP-positive multinucleated (≥ 3 nuclei) cells.

In vitro differentiation of osteoblasts

MC3T3-E1 cells (Chinese Academy of Sciences Cell Bank, Shanghai, China) were

maintained in osteoblastogenic medium (AAPR99-C500, Pythonbio, Guangzhou,

China) with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin sulfate at

37°C with 5% CO_2, and treated with various concentrations of valeric acid (0, 0.001,

0.01, 0.1, 1 mM) for 14 days. Then alkaline phosphatase (Beyotime, Shanghai, China)

staining and alizarin red S (Solarbio, Beijing, China) staining were performed

according to standard techniques to evaluate osteoblast differentiation and

extracellular matrix mineralization, respectively.

Gene expression in osteoclast-like cells and osteoblasts

Total protein and RNA were extracted from osteoclast-like cells and osteoblasts to

examine expression of the selected genes. Protein concentration was determined by

the BCA protein assay kit (Thermo scientific, Rockford, IL, USA). Since NF-κB

signaling pathway was reported to activate osteoclastogenesis [28] and inhibit

osteoblastogenesis [22], and SCFAs can suppress this pathway [34], we explored whether

the suppressive effect and stimulating effect of valeric acid on osteoclast-like cells

and osteoblasts, respectively, were at least partially through inhibition of the NF-κB

signaling pathway. Western blot (WB) analysis was performed with NF-κB signaling

pathway-associated primary antibody targeting NF-κB p65 (Bclonal, Beijing, China)

in osteoclast-like cells and osteoblasts, and GAPDH (Proteintech, Chicago, IL, USA)

was used as a reference protein. After validating the association between valeric acid

and the NF-κB signaling pathway, we further explored whether IL-10 in

osteoclast-like cells and osteoblasts contributed to this association. We examined

IL-10 because it can be increased by SCFAs [34] and inhibit activation of NF-κB [35].

Real-time PCR analysis (SYBR green real time PCR master mix, TOYOBO, Osaka,

Japan) was performed for the transcriptional levels of IL-10. Relative expression of

IL-10 was normalized to mouse-18S expression, and calculated using the comparative

threshold cycle (Ct) method [50]. The primers of IL-10 were

GGAGCTGAGGGTGAAGTTTGA (sense) and GACACAGACTGGCAGCCAAA

(antisense). The primers of mouse-18S were CGATCCGAGGGCCTCACTA (sense)

and AGTCCCTGCCCTTTGTACACA (antisense).

Online resources and abbreviations

Online resources and abbreviations are provided in supplementary information.

References:

1. Singer, A., *et al.*. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. *MAYO CLIN PROC* **90**, 53-62 (2015).

2. Khosla, S., *et al.*. Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. *J BONE MINER RES* **32**, 424-430 (2017).

3. Hendrickx, G., Boudin, E. & Van Hul, W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. *NAT REV RHEUMATOL* **11**, 462-474 (2015).

4. Chen, Y.C., Greenbaum, J., Shen, H. & Deng, H.W. Association Between Gut Microbiota and Bone Health: Potential Mechanisms and Prospective. *J CLIN ENDOCR METAB* **102**, 3635 (2017).

5. Sjogren, K., *et al.*. The gut microbiota regulates bone mass in mice. *J BONE MINER RES* **27**, 1357-1367 (2012).

6. Das, M., *et al.*. Gut microbiota alterations associated with reduced bone mineral density in older adults. *Rheumatology (Oxford)* (2019).

7. Per-Anders Jansson, *et al*. Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet Rheumatology* **3**, E154-E162 (2019).

8. Wang, J., *et al.*. Diversity analysis of gut microbiota in osteoporosis and osteopenia patients. *PEERJ* **5**, e3450 (2017).

9. Nilsson, A.G., Sundh, D., Backhed, F. & Lorentzon, M. Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial. *J INTERN MED* **284**, 307-317 (2018).

10. Lumsden, M.A. The NICE Guideline - Menopause: diagnosis and management. *CLIMACTERIC* **19**, 426-429 (2016).

11. Aguilar, P., Dorador, C., Vila, I. & Sommaruga, R. Bacterioplankton composition in tropical high-elevation lakes of the Andean plateau. *FEMS MICROBIOL ECOL* **94**(2018).

12. Zhao, N., *et al.*. Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome Regression-Based Kernel Association Test. *AM J HUM GENET* **96**, 797-807 (2015).

13. Shi, P., Zhang, A. & Li, H. Regression Analysis for Microbiome Compositional Data. *ANN APPL STAT* **10**(2016).

14. Lucas, S.*, et al.*. Short-chain fatty acids regulate systemic bone mass and protect from

pathological bone loss. *NAT COMMUN* **9**, 55 (2018).

15. LeBlanc, J.G.*, et al.*. Beneficial effects on host energy metabolism of short-chain fatty acids and

vitamins produced by commensal and probiotic bacteria. *MICROB CELL FACT* **16**, 79 (2017).

16. Schepper, J.D.*, et al.*. Probiotics in Gut-Bone Signaling. *ADV EXP MED BIOL* **1033**, 225-247

(2017).

17. Collins, F.L., Rios-Arce, N.D., Schepper, J.D., Parameswaran, N. & McCabe, L.R. The Potential

of Probiotics as a Therapy for Osteoporosis. *Microbiol Spectr* **5**(2017).

18. Grover, S., Del, G.M.F., Stein, C.M. & Ziegler, A. Mendelian Randomization. *Methods Mol Biol*

1666, 581-628 (2017).

19. Kurt, R. & Smolen, J.S. Inflammatory bone loss: pathogenesis and therapeutic intervention. *NAT*

REV DRUG DISCOV **11**, 234-250 (2012).

20. Giridharan, S. & Srinivasan, M. Mechanisms of NF-kappaB p65 and strategies for therapeutic

manipulation. *J Inflamm Res* **11**, 407-419 (2018).

21. Couper, K.N., Blount, D.G. & Riley, E.M. IL-10: the master regulator of immunity to infection. *J*

IMMUNOL **180**, 5771-5777 (2008).

22. Chang, J.*, et al.*. Inhibition of Osteoblast Functions by IKK/NF-κB in Osteoporosis. *NAT MED*

15, 682-689 (2009).

23. Nobel, Y.R.*, et al.*. Metabolic and metagenomic outcomes from early-life pulsed antibiotic

treatment. *NAT COMMUN* **6**, 7486 (2015).

24. Larsen, O.F.A. & Claassen, E. The mechanistic link between health and gut microbiota diversity.

Sci Rep **8**(2018).

25. Sprent, P. *Sign Test*, (2011).

26. Koller, D.L.*, et al.*. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs

associated with bone mineral density in premenopausal women. *J BONE MINER RES* **28**, 547-558

(2013).

27. Cuív, P.Ó.*, et al.*. The gut bacterium and pathobiont Bacteroides vulgatus activates NF-κB in a

human gut epithelial cell line in a strain and growth phase dependent manner. *ANAEROBE* **47**, 209-217

(2017).

28. Yamaguchi, M., Vikulina, T., Arbiser, J.L. & Weitzmann, M.N. Suppression of NF-kappaB

activation by gentian violet promotes osteoblastogenesis and suppresses osteoclastogenesis. *CURR MOL MED* **14**, 783-792 (2014).

29. Bhanu Chandra, M., Salmaan, K., Alex, L. & Wei-Shou, H. Glucose metabolism in mammalian cell culture: new insights for tweaking vintage pathways. *TRENDS BIOTECHNOL* **28**, 476-484 (2010).

30. Boffi, F.M*., et al.*. Effects of chemical ischemia on purine nucleotides, free radical generation, lipids peroxidation and intracellular calcium levels in C2C12 myotube derived from mouse myocytes. *J VET MED SCI* **64**, 483 (2002).

31. Moriarty, D.J.W. *Measurement of Bacterial Growth Rates in Aquatic Systems from Rates of Nucleic Acid Synthesis*, (1986).

32. Rooks, M.G. & Garrett, W.S. Gut microbiota, metabolites and host immunity. *NAT REV IMMUNOL* **16**, 341-352 (2016).

33. Yan, J*., et al.*. Gut microbiota induce IGF-1 and promote bone formation and growth. *Proc Natl Acad Sci U S A* **113**, E7554-E7563 (2016).

34. Park, J.S., Lee, E.J., Lee, J.C., Kim, W.K. & Kim, H.S. Anti-inflammatory effects of short chain fatty acids in IFN-γ-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-κB and ERK signaling pathways. *INT IMMUNOPHARMACOL* **7**, 70-77 (2007).

35. Heyen, J.R., Ye, S., Finck, B.N. & Johnson, R.W. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappaB. *Brain Res Mol Brain Res* **77**, 138-147 (2000).

36. Yuille, S., Reichardt, N. & Panda, S. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. *PLOS ONE* **13**, e201073 (2018).

37. Li, Y*., et al.*. Gut commensal derived-valeric acid protects against radiation injuries. *Gut Microbes*, 1-18 (2020).

38. Sandra, M. & Macfarlane, G.T. Regulation of short-chain fatty acid production. *P NUTR SOC* **62**, 67-72 (2003).

39. Coyte, K.Z. & Rakoff-Nahoum, S. Understanding Competition and Cooperation within the Mammalian Gut Microbiome. *CURR BIOL* **29**, R538-R544 (2019).

40. Buchfink, B., Xie, C. & Huson, D.H. Fast and sensitive protein alignment using DIAMOND. *NAT METHODS* **12**, 59-60 (2015).

41. Huson, D., Auch, A.J. & Schuster, S. MEGAN analysis of metagenomic data. *GENOME RES* **17**, 377-386 (2007).

42. Jain, M*., et al.*. The importance of rare species: a trait-based assessment of rare species contributions to functional diversity and possible ecosystem function in tall-grass prairies. *ECOL EVOL* **4**, 104-112 (2014).

43. Piercy, K.L. & Troiano, R.P. Physical Activity Guidelines for Americans From the US Department of Health and Human Services. *Circ Cardiovasc Qual Outcomes* **11**, e5263 (2018).

44. Du, Y., Zhao, L.J., Xu, Q., Wu, K.H. & Deng, H.W. Socioeconomic status and bone mineral density in adults by race/ethnicity and gender: the Louisiana osteoporosis study. *Osteoporos Int* **28**, 1699-1709 (2017).

45. Zhou, S*., et al.*. Age-dependent variations of cancellous bone in response to ovariectomy in C57BL/6J mice. *EXP THER MED* **15**, 3623-3632 (2018).

46. Magnus, M.C *et al*. Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study. *BMJ* **361**, - (2018).

47. Sanna, S*., et al.*. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *NAT GENET* **51**, 600-605 (2019).

48. Sudmant, P.H*., et al.*. An integrated map of structural variation in 2,504 human genomes. *NATURE* **526**, 75-81 (2015).

49. Bowden, J., Davey, S.G., Haycock, P.C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *GENET EPIDEMIOL* **40**, 304-314 (2016).

50. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. *NAT PROTOC* **3**, 1101-1108 (2008).

Acknowledgement

HW Deng and H Shen were partially supported by grants from the National Institutes of Health [U19AG05537301, R01AR069055, P20GM109036, R01MH104680, R01AG061917], and the Edward G. Schlieder Endowment and the Drs. W. C. Tsai and P. T. Kung Professorship from Tulane University. J Shen was partially supported by grants from the Science and Technology Program of Guangzhou, China [201604020007], and the National Natural Science Foundation of China [81770878]. HM Xiao was partially supported by the National Key R&D Program of China (2016YFC1201805 and 2017YFC1001100).

We thank Feng-Zhu Sun, Guo-Zhen Wang, Jun Wang, Wei-Chang Huang, Zun Wang, Yong Liu, Lin-Dong Jiang, Rui-Ke Liu, Zhi-Mei Feng, Yuan-Yuan Hu, Lin-Ping Peng and Chun-Ping Zeng for their suggestions and supports for this study.

Author contributions

HWD conceived, designed, initiated and directed the whole project. JG, QZ, KJS, XHM, FYL, and CLG contributed to the data analysis. JS and HMX managed the study done in their institutions. DYP, ZC, and ZFL performed clinical diagnosis and recruited subjects. CP, XJX, YCC, RZ, XFW, ZXA, JML, YQS, and YHZ collected samples and clinical phenotypes. SJY conducted animal experiments. XL drafted the manuscript. HWD revised, rewrote/re-structured some sections and finalized the manuscript. NJY, QZ, BYG, HML, WQL, CJP, XMS and HS contributed to text revision and/or discussion.

Author information

3 The authors declare no competing financial interests.

4 Correspondence and requests for materials should be addressed to Hong-Wen Deng

5 (hdeng2@tulane.edu), Jie Shen (shenjiedr@163.com) and Hong-Mei Xiao

6 (hmxiao@csu.edu.cn).

Table 1. Characteristics of the Chinese study cohort

Phenotypes	Max	Min	Mean	Standard Deviation
Age (years)	64.59	41.47	52.85	2.92
BMI (kg/m^2)	33.73	16.42	22.97	2.87
YSM (years)	8.99	0.06	1.96	0.94
FSH (mIU/mL)	208.20	1.08	76.24	32.63
L1-L4 BMD (g/cm^2)	1.85	0.69	1.05	0.16
HTOT BMD (g/cm^2)	1.36	0.61	0.93	0.12
FN BMD (g/cm^2)	1.26	0.58	0.86	0.12
UD-RU BMD (g/cm^2)	0.61	0.22	0.40	0.06

Abbreviations:

YSM - years since menopause; FSH - follicle stimulating hormone; BMI - body mass index; BMD - bone mineral density; L1-L4 - lumbar spine; HTOT - left total hip; FN - femoral neck; UD-RU - ultra-distal radius and ulna.

1 **Table 2. Correlation between GM functional capacity and BMD variation**

Module ID	γ	p-value	Q-value	Module names	Phenotypes
M00002	-0.122	0.007	0.234	Glycolysis	L1-L4 BMD
M00048	-0.119	0.008	0.234	IMP biosynthesis	L1-L4 BMD
M00855	-0.119	0.008	0.234	Glycogen degradation	L1-L4 BMD
M00002	-0.118	0.009	0.153	Glycolysis	UD-RU BMD
M00003	-0.119	0.008	0.153	Gluconeogenesis	UD-RU BMD
M00050	-0.143	0.002	0.079	GTP biosynthesis	UD-RU BMD
M00727	-0.135	0.003	0.079	CAMP resistance	UD-RU BMD

Note:

γ - coefficient of the partial Spearman correlation between GM functional module and
phenotype; p-value - p-value of the coefficient in partial Spearman correlation
analysis; Q-value - p-value adjusted by false discovery rate; Glycolysis -
core module involving three-carbon compounds; IMP biosynthesis
- PRPP + glutamine → IMP; Glycogen degradation - glycogen → glucose-6P;
Gluconeogenesis - oxaloacetate → fructose-6P; GTP biosynthesis - IMP → GDP,
GTP; CAMP resistance - N-acetylmuramoyl-L-alanine amidase AmiA and AmiC. We
only tested the modules whose relative abundance > 0.10%.

Abbreviations:

GM - gut microbiota; BMD - bone mineral density; L1-L4 - lumbar spine; UD-RU -
ultra-distal radius and ulna; PRPP - phosphoribosylpyrophosphate; IMP - inosine
monophosphate; GDP - guanosine 5'-diphosphate; GTP - guanosine 5'-triphosphate;
CAMP - cationic antimicrobial peptide.

1   **Figure legends**

2   **Figure 1. Unigene accumulation curve, bacterial species composition and**
3   **correlation**

Figure 1

(a)

(b)

(c)

1 (a) Unigene accumulation curve: the number of unigenes (y-axis) was plotted against the number of samples (x-axis). (b) Bacterial species

2 composition in the study cohort composed of rare and non-rare bacterial species. Different colours represent different bacterial species.

3 Numbers in parentheses indicate the proportion of each bacterial species. "Rare species" include all those bacterial species with relative

4 abundances less than 0.10%. (c) Heatmap of co-occurrence between the relative abundances of non-rare species. Numbers in the plot

5 represent Spearman correlation coefficients of pairwise two bacterial species.

Figure 2. *Bacteroides vulgatus* regulates bone remodeling in mice *in vivo*

Figure 2

Changes in various bone-associated phenotypes in mice gavaged with *B. vulgatus* or normal saline (NS) for 8 weeks (performed at age of 8 weeks after ovariectomy): (a) bone mineral density (BMD) of the 5th lumbar vertebral body; (b) serum osteocalcin (OC) concentrations; (c) serum C-telopeptide of type I collagen (CTX-I) concentrations; (d) representative histomorphology of the 5th lumbar vertebral body using hematoxylin-eosin staining. Red arrows point to trabecular bone; (e) representative micro-computed tomograph images of the 5th lumbar vertebral body by three-dimensional reconstructions. (Note: in A, B, and C, n = 18, and ∗ indicates *p*-value < 0.05.)

Figure 3. Valeric acid influences osteoclast and osteoblast differentiation *in vitro*

Figure 3

Effects of valeric acid (VA) on osteoclast differentiation of RAW264.7 cells (induced by receptor activator of nuclear factor-κB ligand [RANKL]) and osteoblast differentiation of MC3T3-E1 cells: (a) Microscopic images of tartrate-resistant acid phosphatase staining of osteoclast-like cells induced from RAW264.7 cells after 5 days of osteoclastogenesis with/without VA treatment. Red arrows indicate osteoclast-like cells. (b) Alkaline phosphatase (ALP) staining for osteoblast differentiation and alizarin red S (AR-S) staining for extracellular matrix mineralization by MC3T3-E1 cells after 14 days of osteoblastogenesis with/without VA treatment; (c) Western blot of NF-κB p65 protein in osteoclast-like cells with/without VA treatment; (d) Western blot of NF-κB p65 protein in osteoblasts with/without VA treatment; the "induce" means the MC3T3-E1 cells were induced into osteoblasts by osteoblastogenic medium without VA; (e) IL-10 mRNA expression in osteoclast-like cells with/without VA; (f) IL-10 mRNA expression in osteoblasts with/without VA. ∗ indicates p-value < 0.05, and ∗∗ means p-value < 0.01.